McKesson Stock (NYSE:MCK)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$717.76

52W Range

$464.42 - $731.18

50D Avg

$702.33

200D Avg

$608.54

Market Cap

$91.43B

Avg Vol (3M)

$1.04M

Beta

0.49

Div Yield

$2.84 (0.39%)

MCK Company Profile


McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Show More

Industry

Medical - Distribution

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

44,000

IPO Date

Nov 10, 1994

Website

MCK Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceMar 25Mar 24Mar 23
Medical-Surgical Solutions Segment$11.39B$11.31B$11.11B
Prescription Technology Solutions$5.22B$4.77B$4.39B
U.S. Pharmaceutical Segment$327.72B$278.74B$240.62B
International Segment$14.72B$14.13B$20.60B
Prescription Technology Solutions Segment--$4.39B

Fiscal year ends in Mar 24 | Currency in USD

MCK Financial Summary


Mar 24Mar 23Mar 22
Revenue$308.95B$276.71B$263.97B
Operating Income$3.91B$4.38B$2.85B
Net Income$3.00B$3.56B$1.11B
EBITDA$4.67B$5.74B$3.11B
Basic EPS$22.54$25.23$7.31
Diluted EPS$22.39$25.04$7.23

Fiscal year ends in Mar 24 | Currency in USD

Latest Earnings Call Transcripts


Q4 25May 08, 25 | 4:30 PM
Q3 25Feb 05, 25 | 4:30 PM
Q2 25Nov 06, 24 | 4:30 PM

Peer Comparison


TickerCompany
EDAPEDAP TMS S.A.
OMIOwens & Minor, Inc.
CAHCardinal Health, Inc.
PDCOPatterson Companies, Inc.
ZYXIZynex, Inc.
HSICHenry Schein, Inc.